POCT Influenza & RSV

Purpose:
A number of POCT devices used for rapid screening of respiratory viral infections including seasonal influenza are now widely available. The viral testing targets in POCT platforms can be single, dual or multiplex; the most common being Influenza A (and/or subtypes) and B alone, or Influenza A and B with Respiratory Syncytial Virus (RSV). Platforms tend to be based on nucleic acid amplification technologies (NAAT), which generally have improved sensitivity compared to first generation Antigen based lateral flow devices.

Studies have shown that their use in well designed and defined settings with appropriate governance arrangements can lead to improved patient triage, better use of isolation rooms during periods of winter pressure, more targeted use of antivirals, reduction in unnecessary antibiotic use and a reduced length of hospital stay.

Scope:
Three liquid human serum samples are distributed monthly over the autumn and winter season with a minimum of 16 samples distributed over the year covering a wide viral load. The samples consist of a buffered viral transport medium containing inactivated Influenza A (both H1N1 and H3N2 subtypes), influenza B or RSV. A range of viral loads are distributed including samples with multiple viruses. The programme assesses the sensitivity and specificity of the test at the individual site and the overall performance of the method.

Key Features:

Liquid stable samples are supplied ready to use; no pre-analytical preparation is required.
Qualitative reporting for Influenza A, Influenza B and RSV available.